Side-effects of inotuzumab ozogamicin

Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses the side-effects of inotuzumab ozogamicin, which targets CD22 in adult acute lymphoblastic leukemia (ALL) patients. According to Prof Martinelli, due to the specificity of the drug, severe side-effects are not to be expected. This means that the drug can also be given to elderly patients with acute leukemia. The majority of patients, 82%, responded very well to the drug according to Prof Martinelli.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

Share this video  
Similar topics